SG Americas Securities
RGLS

SG Americas Securities’s Regulus Therapeutics RGLS Stock Holding History

SG Americas Securities’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,696
Closed -$33K – 3481
2025
Q1 		$33K Sell
18,696
-7,764
-29% -$10.2K ﹤0.01% 3322
2024
Q4 		$42K Buy
26,460
+5,660
+27% +$8.69K ﹤0.01% 2936
2024
Q3 		$33K Buy
+20,800
New +$34.4K ﹤0.01% 3313
2020
Q3 		– Sell
-3,500
Closed -$24K – 3326
2020
Q2 		$24K Buy
+3,500
New +$22.9K ﹤0.01% 3594
2016
Q4 		– Sell
-94
Closed -$37K – 3399
2016
Q3 		$37K Buy
+94
New +$38.7K ﹤0.01% 3207
2015
Q4 		– Sell
-87
Closed -$68K – 2935
2015
Q3 		$68K Buy
+87
New +$89.3K ﹤0.01% 1934
2015
Q1 		– Sell
-82
Closed -$157K – 2981
2014
Q4 		$157K Buy
+82
New +$146K ﹤0.01% 2616

Other funds holding RGLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

SG Americas Securities's RGLS Position: Q2 2025 in Review

SG Americas Securities sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 18,696 shares — an estimated $33K sold.

SG Americas Securities first reported a position in RGLS in Q4 2014 and held it in 7 quarters. The position peaked at $157K in Q4 2014. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.

  • SG Americas Securities reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • SG Americas Securities sold 18,696 Regulus Therapeutics shares in Q2 2025, an estimated $33K.
  • SG Americas Securities first reported a position in Regulus Therapeutics in Q4 2014 and held it in 7 quarters.
  • SG Americas Securities's Regulus Therapeutics position peaked at $157K in Q4 2014.
  • 0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.

Based on SG Americas Securities's 13F filing for Q2 2025, filed 8 Aug 2025.